UNSPSC 51162325: Acetaminophen/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162325 Acetaminophen/pseudoephedrine is a Commodity code that does not align with recent state and local procurement activity posted under this classification. The two recent opportunities tagged to this code—a Seminole County, Florida IFB for naloxone and drug deactivation systems, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—represent naloxone procurement and broad pharmaceutical supply agreements rather than acetaminophen/pseudoephedrine specifically. The mismatch suggests either misclassification by the issuing bodies or that this Commodity code is not in active use for state and local solicitation of the product it nominally describes.

The geographic activity present includes Florida and Minnesota, with the MMCAP opportunity spanning multiple state and local facilities across participating jurisdictions including Oregon. Issuing bodies include a county health department (Seminole County) and a multistate cooperative purchasing vehicle administered by a state procurement office (Minnesota Department of Administration). The Seminole County IFB, posted June 30, 2026 with a July 26, 2023 due date, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually on a fixed-fee basis with a two-year initial term and one-year renewal option. The MMCAP RFP, posted January 20, 2026 with a March 26, 2026 proposal deadline, established multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with awarded vendors effective July 1, 2026 and a two-year contract term. Neither opportunity directly addresses acetaminophen/pseudoephedrine procurement, indicating limited current relevance of this code to active state and local contracting.